NeuroOne Medical Technologies (NeuroOne Medical Technologies) ROCE % : -252.44% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is NeuroOne Medical Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NeuroOne Medical Technologies's annualized ROCE % for the quarter that ended in Dec. 2023 was -252.44%.

NeuroOne Medical Technologies ROCE % Historical Data

The historical data trend for NeuroOne Medical Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroOne Medical Technologies ROCE % Chart

NeuroOne Medical Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROCE %

Get a 7-Day Free Trial

-1,048.16

-217.14

-121.74

-149.18

NeuroOne Medical Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-79.07	-200.06	-290.53	-245.49	-252.44

NeuroOne Medical Technologies ROCE % Calculation

NeuroOne Medical Technologies's annualized ROCE % for the fiscal year that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	-11.955	/	( ( (12.823 - 3.099)	+	(8.097 - 1.793) )	/ 2 )
	=	-11.955	/	( (9.724	+	6.304)	/ 2 )
	=	-11.955	/	8.014
	=	-149.18 %

NeuroOne Medical Technologies's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-13.56	/	( ( (8.097 - 1.793)	+	(5.822 - 1.383) )	/ 2 )
	=	-13.56	/	( ( 6.304	+	4.439 )	/ 2 )
	=	-13.56	/	5.3715
	=	-252.44 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

NeuroOne Medical Technologies (NAS:NMTC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NeuroOne Medical Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of NeuroOne Medical Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroOne Medical Technologies Corp (NAS:NMTC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7599 Anagram Dr., Eden Prairie, MN, USA, 55344

Website

https://www.n1mtc.com

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Executives

Mark Christianson	10 percent owner, officer: VP, Business Dev and Marketing	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Ronald W. Mcclurg	officer: Chief Financial Officer	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa	director, officer: CEO and President	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Hijaz Haris	officer: VP of Marketing	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
Morgan C. Frank	10 percent owner	2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02110
Manchester Explorer, L.p.	10 percent owner	MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
James E Besser	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Manchester Management Pr, Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Edward Andrle	director	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344
Wade Fredrickson	10 percent owner	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Steve Mertens	officer: Chief Technology Officer	10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Scott Heuler	officer: Vice President of Sales	10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Paul Buckman	director	12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Suraj Kalia	director	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347